AbbVie competitors and similar companiesClear all
Astellas Pharma's competitors and similar companies include Gilead Sciences, Immunomedics, Sanofi, Amgen, Bristol-Myers Squibb, Abbott, Merck Group, GSK, Novartis, Roche and Johnson & Johnson.
 Astellas Pharma Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions. |  Gilead Sciences Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines. |  Immunomedics Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. |  Sanofi Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions. |  Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotech company discovering, developing, manufacturing, and delivering human therapeutics products. |  Bristol-Myers Squibb Bristol-Myers Squibb is a company focused that provides biopharmaceutical products. |  Abbott Abbott Laboratories is a healthcare company that develops, manufactures, and sells health care products. |  GSK GSK (GlaxoSmithKline) is a science-led healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Roche Roche Holding is the holding company of F. Hoffmann-La Roche, a biotech company operating through 2 segments: Pharmaceuticals and Diagnostics. |  Johnson & Johnson Johnson & Johnson is a global holding company that engages in the research and development, manufacture, and sale of a range of products in the healthcare field. | ||
Founding Date | Founding Date 1923 | Founding Date 1987 | Founding Date 1982 | Founding Date 2004 | Founding Date 1980 | Founding Date 1887 | Founding Date 1894 | Founding Date 1668 | Founding Date 2000 | Founding Date 1996 | Founding Date 1896 | Founding Date 1886 |
Type | Type Public | Type Public | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||||||||
Locations | Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Vilvoorde, BE São Paulo, BR Markham, CA Beijing, CN see more | Locations Foster City, US HQ Buenos Aires, AR Melbourne, AU Wien, AT Machelen, BE São Paulo, BR Edmonton, CA see more | Locations Morris Plains, US HQ | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Sydney, AU Wien, AT Diegem, BE Santo Amaro, BR see more | Locations New York, US HQ Wien, AT Braine L'alleud, BE Bruxelles, BE São Paulo, BR Montréal, CA Shanghai, CN see more | Locations Abbott Park, US HQ Tiranë, AL Buenos Aires, AR Yerevan, AM Doncaster, AU East Brisbane, AU Macquarie Park, AU see more | Locations Darmstadt, DE HQ Hydra, DZ Buenos Aires, AR Bayswater, AU Macquarie Park, AU Wien, AT Manama, BH see more | Locations Brentford, GB HQ Boumerdes, DZ San Fernando, AR Abbotsford, AU Boronia, AU Ermington, AU Wien, AT see more | Locations New Brunswick, US HQ Buenos Aires, AR San Isidro, AR Yerevan, AM Sydney, AU Ultimo, AU Wien, AT see more | |||
Employees | Employees 15,4553% decrease | Employees 14,4006% increase | Employees 1324% decrease | Employees 95,4424% decrease | Employees 24,200 | Employees 32,2006% increase | Employees 113,0004% increase | Employees 59,3086% decrease | Employees 90,0964% decrease | Employees 104,3231% decrease | Employees 100,9201% decrease | Employees 141,7005% increase |
Valuation ($) | Valuation ($) 27.6 b | Valuation ($) 105 b | Valuation ($) N/A | Valuation ($) 121.7 b | Valuation ($) 142.9 b | Valuation ($) 154 b | Valuation ($) 191.7 b | Valuation ($) 89.8 b | Valuation ($) 71.3 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 439.8 b |
Twitter followers | Twitter followers 50.4 k | Twitter followers 73.1 k | Twitter followers 579 | Twitter followers 150.8 k | Twitter followers 124.4 k | Twitter followers 157.3 k | Twitter followers 121.7 k | Twitter followers 24.6 k | Twitter followers 242.2 k | Twitter followers 302.8 k | Twitter followers 247.4 k | Twitter followers 250.2 k |
Number of tweets (last 30 days) | Number of tweets (last 30 days) 25 | Number of tweets (last 30 days) 1 | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) 21 | Number of tweets (last 30 days) 42 | Number of tweets (last 30 days) 11 | Number of tweets (last 30 days) 139 | Number of tweets (last 30 days) 32 | Number of tweets (last 30 days) 38 | Number of tweets (last 30 days) 32 | Number of tweets (last 30 days) 29 | Number of tweets (last 30 days) 30 |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) 5.8 | Average likes per tweet (last 30 days) 22 | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) 8 | Average likes per tweet (last 30 days) 5.5 | Average likes per tweet (last 30 days) 8.5 | Average likes per tweet (last 30 days) 4.1 | Average likes per tweet (last 30 days) 1.9 | Average likes per tweet (last 30 days) 11.5 | Average likes per tweet (last 30 days) 5.9 | Average likes per tweet (last 30 days) 5.2 | Average likes per tweet (last 30 days) 4.7 |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) 96% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) 71.43% | Percentage of tweets with engagement (last 30 days) 92.86% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 27.34% | Percentage of tweets with engagement (last 30 days) 90.63% | Percentage of tweets with engagement (last 30 days) 73.68% | Percentage of tweets with engagement (last 30 days) 71.88% | Percentage of tweets with engagement (last 30 days) 62.07% | Percentage of tweets with engagement (last 30 days) 50% |
Alexa Website Rank | Alexa Website Rank 330601 | Alexa Website Rank 187202 | Alexa Website Rank N/A | Alexa Website Rank 155495 | Alexa Website Rank 118547 | Alexa Website Rank 106029 | Alexa Website Rank 78401 | Alexa Website Rank 70623 | Alexa Website Rank 23804 | Alexa Website Rank 129099 | Alexa Website Rank 46160 | Alexa Website Rank 17146 |
Employee Rating | Employee Rating 4.2 | Employee Rating 3.8 | Employee Rating 2.9 | Employee Rating N/A | Employee Rating 4.1 | Employee Rating 3.9 | Employee Rating 3.9 | Employee Rating 4.1 | Employee Rating 4 | Employee Rating 4.2 | Employee Rating 4.2 | Employee Rating 4.2 |
Financial | ||||||||||||
Revenue (est.) | Revenue (est.) ¥1.3t (FY, 2022) | Revenue (est.) $27.3b (FY, 2021) | Revenue (est.) $295k (FY, 2019) | Revenue (est.) €37.8b (FY, 2021) | Revenue (est.) $26b (FY, 2021) | Revenue (est.) $46.4b (FY, 2021) | Revenue (est.) $43.1b (FY, 2021) | Revenue (est.) €19.7b (FY, 2021) | Revenue (est.) £34.1b (FY, 2021) | Revenue (est.) $52.9b (FY, 2021) | Revenue (est.) CHF62.8b (FY, 2021) | Revenue (est.) $93.8b (FY, 2021) |
Cost of goods | Cost of goods ¥173.3b (FY, 2022) | Cost of goods $6.6b (FY, 2021) | Cost of goods N/A | Cost of goods (€10.7b) (FY, 2021) | Cost of goods $6.5b (FY, 2021) | Cost of goods $9.9b (FY, 2021) | Cost of goods $18.5b (FY, 2021) | Cost of goods €7.4b (FY, 2021) | Cost of goods £11.6b (FY, 2021) | Cost of goods $9.7b (FY, 2021) | Cost of goods (CHF15.5b) (FY, 2021) | Cost of goods $29.9b (FY, 2021) |
Gross profit | Gross profit ¥1.2t (FY, 2022) | Gross profit $20.7b (FY, 2021) | Gross profit $295k (FY, 2019) | Gross profit €28.9b (FY, 2021) | Gross profit $19.5b (FY, 2021) | Gross profit $36.4b (FY, 2021) | Gross profit $24.5b (FY, 2021) | Gross profit €12.3b (FY, 2021) | Gross profit £22.5b (FY, 2021) | Gross profit $45.1b (FY, 2021) | Gross profit CHF50.4b (FY, 2021) | Gross profit $63.9b (FY, 2021) |
Net income | Net income ¥124.1b (FY, 2022) | Net income $6.2b (FY, 2021) | Net income ($357.3m) (FY, 2019) | Net income €6.2b (FY, 2021) | Net income $5.9b (FY, 2021) | Net income $7b (FY, 2021) | Net income $7.1b (FY, 2021) | Net income €3.1b (FY, 2021) | Net income £5.1b (FY, 2021) | Net income $24b (FY, 2021) | Net income CHF14.9b (FY, 2021) | Net income $20.9b (FY, 2021) |
Operating ⚠ | ||||||||||||
Countries | Countries N/A | Countries 35 (FY, 2021) | Countries N/A | Countries N/A | Countries 100 (FY, 2020) | Countries N/A | Countries N/A | Countries 66 (FY, 2021) | Countries 92 (FY, 2021) | Countries N/A | Countries N/A | Countries N/A |
Manufacturing Facilities | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 8 (FY, 2021) | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 85 (FY, 2021) |
Manufacturing Sites | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites 90 (FY, 2021) | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites 23 (FY, 2019) | Manufacturing Sites N/A |
Patents (US) | Patents (US) N/A | Patents (US) N/A | Patents (US) 405 (Sep, 2022) | Patents (US) N/A | Patents (US) 31 (FY, 2020) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 20 (FY, 2020) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 16 (FY, 2021) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase I Trials Products (Immunology) | Phase I Trials Products (Immunology) 1 (Oct, 2020) | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) 6 (FY, 2021) | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) 4 (Jan, 2022) | Phase I Trials Products (Immunology) N/A |
Phase I Trials Products (Neuroscience) | Phase I Trials Products (Neuroscience) N/A | Phase I Trials Products (Neuroscience) N/A | Phase I Trials Products (Neuroscience) N/A | Phase I Trials Products (Neuroscience) N/A | Phase I Trials Products (Neuroscience) N/A | Phase I Trials Products (Neuroscience) 4 (FY, 2021) | Phase I Trials Products (Neuroscience) N/A | Phase I Trials Products (Neuroscience) N/A | Phase I Trials Products (Neuroscience) N/A | Phase I Trials Products (Neuroscience) N/A | Phase I Trials Products (Neuroscience) 5 (Jan, 2022) | Phase I Trials Products (Neuroscience) N/A |
Phase I Trials Products (Oncology) | Phase I Trials Products (Oncology) 1 (FY, 2020) | Phase I Trials Products (Oncology) 7 (FY, 2019) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 9 (FY, 2021) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 20 (FY, 2021) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 36 (Jan, 2022) | Phase I Trials Products (Oncology) N/A |
Phase I Trials Products (Other) | Phase I Trials Products (Other) 3 (Oct, 2020) | Phase I Trials Products (Other) N/A | Phase I Trials Products (Other) N/A | Phase I Trials Products (Other) N/A | Phase I Trials Products (Other) N/A | Phase I Trials Products (Other) N/A | Phase I Trials Products (Other) N/A | Phase I Trials Products (Other) N/A | Phase I Trials Products (Other) N/A | Phase I Trials Products (Other) N/A | Phase I Trials Products (Other) 2 (Jan, 2022) | Phase I Trials Products (Other) N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 5 (FY, 2020) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 6 (FY, 2021) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase II Trials Products (Immunology) | Phase II Trials Products (Immunology) 1 (Oct, 2020) | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) 6 (FY, 2021) | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) 6 (Jan, 2022) | Phase II Trials Products (Immunology) N/A |
Phase II Trials Products (Oncology) | Phase II Trials Products (Oncology) 1 (FY, 2020) | Phase II Trials Products (Oncology) 1 (FY, 2021) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 12 (FY, 2021) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 15 (FY, 2021) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 11 (Jan, 2022) | Phase II Trials Products (Oncology) N/A |
Phase II Trials Products (Other) | Phase II Trials Products (Other) 2 (Oct, 2020) | Phase II Trials Products (Other) N/A | Phase II Trials Products (Other) N/A | Phase II Trials Products (Other) N/A | Phase II Trials Products (Other) N/A | Phase II Trials Products (Other) N/A | Phase II Trials Products (Other) N/A | Phase II Trials Products (Other) N/A | Phase II Trials Products (Other) N/A | Phase II Trials Products (Other) N/A | Phase II Trials Products (Other) 3 (Jan, 2022) | Phase II Trials Products (Other) N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 9 (FY, 2021) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2020) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2021) | Phase III Trials Products 54 (FY, 2021) | Phase III Trials Products N/A | Phase III Trials Products N/A |
Phase III Trials Products (Immunology) | Phase III Trials Products (Immunology) 1 (Oct, 2020) | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) 3 (FY, 2021) | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) 7 (Jan, 2022) | Phase III Trials Products (Immunology) N/A |
Phase III Trials Products (Oncology) | Phase III Trials Products (Oncology) 4 (Oct, 2020) | Phase III Trials Products (Oncology) 4 (FY, 2021) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 7 (FY, 2021) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 27 (FY, 2021) | Phase III Trials Products (Oncology) 27 (Jan, 2022) | Phase III Trials Products (Oncology) N/A |
Phase III Trials Products (Other) | Phase III Trials Products (Other) 1 (Oct, 2020) | Phase III Trials Products (Other) N/A | Phase III Trials Products (Other) N/A | Phase III Trials Products (Other) N/A | Phase III Trials Products (Other) N/A | Phase III Trials Products (Other) N/A | Phase III Trials Products (Other) N/A | Phase III Trials Products (Other) N/A | Phase III Trials Products (Other) N/A | Phase III Trials Products (Other) N/A | Phase III Trials Products (Other) 1 (Jan, 2022) | Phase III Trials Products (Other) N/A |
Products | Products N/A | Products 21 (FY, 2021) | Products N/A | Products N/A | Products N/A | Products N/A | Products 1.5 k (FY, 2019) | Products 300 k (FY, 2021) | Products N/A | Products N/A | Products N/A | Products N/A |
Research and Development Centers | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers 11 (FY, 2021) | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers 29 (FY, 2019) | Research and Development Centers N/A |
Suppliers | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers 68 k (FY, 2019) | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers 37.5 k (FY, 2021) | Suppliers N/A | Suppliers N/A | Suppliers N/A |
US FDA Breakthrough Therapy Designations | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations 6 (FY, 2017) | US FDA Breakthrough Therapy Designations 2 (FY, 2021) | US FDA Breakthrough Therapy Designations N/A |
Funding | ||||||||||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 30m | Total funding raised $ 310m | Total funding raised N/A | Total funding raised $ 15.5m | Total funding raised N/A | Total funding raised $ 121m | Total funding raised N/A | Total funding raised $ 6.5m | Total funding raised $ 7.8b | Total funding raised N/A |
For sources of this data, please see the company profile
View company profiles
Gilead Sciences
HQ
Foster City, US
Employees
14,400↑ 6% increase
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.
View companyImmunomedics
HQ
Morris Plains, US
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
View companySanofi
HQ
Paris, FR
Employees
95,442↓ 4% decrease
Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.
View companyAmgen
HQ
Thousand Oaks, US
Employees
24,200
Amgen (formerly known as Applied Molecular Genetics) is a biotech company discovering, developing, manufacturing, and delivering human therapeutics products.
View company